Skip to main content
TipRanks
Go Ultimate75% OFF

Oruka Therapeutics (0H79) Share Price & Analysis

0 Followers

0H79 Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
$6.73B
Enterprise Value
$5.05B
Total Cash (Recent Filing)
$920.28M
Total Debt (Recent Filing)
$2.93M
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
Mar 11, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Phase 2b Clinical Efficacy

Strong Phase 2b efficacy and favorable safety support advancing ORKA-001 toward Phase 3 and potentially differentiate it from existing psoriasis biologics. If replicated, high disease-clearance rates and infrequent dosing could strengthen adoption and create a durable commercial opportunity.

Cash Resources

A substantial cash and securities position gives Oruka the resources to continue clinical development and pursue a planned biologics license application without immediate dependence on operating revenue. This supports execution through important value-creating milestones over the next several quarters.

Low Financial Leverage

Extremely low leverage preserves financial flexibility because limited debt reduces fixed obligations and refinancing pressure. The larger equity base can support continued investment in clinical programs, although the company must ultimately convert that capital into products and future commercial returns.

Bears Say

Pre-revenue Business Model

The absence of product revenue means Oruka currently relies on capital rather than commercial cash inflows to fund operations. Until a candidate is approved and launched, financial performance will remain tied to clinical execution, regulatory progress, and access to external funding.

Widening Net Losses

Rapidly widening losses show that operating investment is increasing faster than any developing revenue base, leaving near-term earnings visibility weak. Continued clinical and overhead spending may be appropriate for the company’s stage, but it raises the capital required before a product can generate returns.

Substantial Cash Burn

Persistent and worsening negative free cash flow indicates that Oruka is consuming substantial cash while its pipeline remains pre-commercial. Unless development produces a revenue inflection or strategic funding event, ongoing burn increases the likelihood of future financing and potential shareholder dilution.

Oruka Therapeutics News

0H79 FAQ

What is Oruka Therapeutics’s market cap?
Oruka Therapeutics’s market cap is $6.73B.
When is Oruka Therapeutics’s upcoming earnings report date?
Oruka Therapeutics’s next earnings report is estimated for Mar 11, 2027 (not yet confirmed), which is in 113 days.
How were Oruka Therapeutics’s earnings last quarter?
Oruka Therapeutics released its earnings results on Nov 09, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.6 by -$0.03.
Is Oruka Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Oruka Therapeutics pay dividends?
Oruka Therapeutics does not currently pay dividends.
What is Oruka Therapeutics’s EPS estimate?
Oruka Therapeutics’s EPS estimate is -0.75.
What happened to Oruka Therapeutics’s price movement after its last earnings report?
Oruka Therapeutics reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.6. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Oruka Therapeutics?
Hedge funds hold Oruka Therapeutics shares: the largest hedge-fund position in Oruka Therapeutics is 1,377,214,982 shares, and hedge funds increased their holdings by 350.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology